Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine
Casey L. O’Connell(University of Southern California), Kirsten Grønbæk(University of Copenhagen), Jakob Werner Hansen(Rigshospitalet), Vu H. Duong(University of Maryland, Baltimore), Ashkan Emadi(University of Maryland, Baltimore), H. Josh Jang(Van Andel Institute), Staffan Holmberg-Thydén(Technical University of Denmark), Imran Siddiqi(University of Southern California), Sine Reker Hadrup(Herlev Hospital), Andreas Due Ørskov(Zealand University Hospital), Maria R. Baer(University of Maryland, Baltimore), Ben Youngblood(St. Jude Children's Research Hospital), Jack B. Cowland(Copenhagen University Hospital), Stephen B. Baylin(Johns Hopkins University), Denice Tsao‐Wei(Children's Hospital of Los Angeles), Jean‐Pierre J. Issa(Coriell Institute For Medical Research), Kristin Horwood(University of Southern California), Galen Hostetter(Van Andel Institute), Patricia Kropf(Fox Chase Cancer Center), Brett T. Brinker(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Sunil Kumar Saini(Unknown), Peter A. Jones(Van Andel Institute), Ryan S. Burgos(Van Andel Institute)
Cited by 27
Related Papers
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
The Role of DNA Methylation in Mammalian Epigenetics
|Science|2001|2.1k
Incidence and functional consequences of <i>hMLH1</i> promoter hypermethylation in colorectal carcinoma
|Proceedings of the National Academy of Sciences|1998|1.9k